Harvard Bioscience INC Form 4 insider transactions

Harvard Bioscience director Katherine A. Eade was granted 16,556 restricted stock units as part of standard equity compensation.

Harvard Bioscience Director William Snider reported the acquisition of 16,556 restricted stock units.

Stephen J. DeNelsky, a Director at Harvard Bioscience Inc., reported the acquisition of 16,556 restricted stock units.

Robert E. Gagnon, a Director at Harvard Bioscience Inc., was granted 16,556 restricted stock units, vesting prior to the next annual meeting or one year from grant.

Harvard Bioscience, Inc. reports a Form 4 filing detailing the acquisition of restricted stock units by Director Seth Benson.

Harvard Bioscience CFO Mark Frost reported the acquisition of 30,000 restricted stock units and updated his total beneficial ownership to 47,500 shares following a recent reverse stock split.

Harvard Bioscience's Chief Financial Officer, Mark T. Frost, purchased 5,000 shares of common stock at $5 per share following a 10-for-1 reverse stock split.

Harvard Bioscience CEO John D. Duke reported an increase in his beneficial ownership, including new restricted stock unit awards and a common stock purchase.

Harvard Bioscience Director Stephen J. DeNelsky purchased 10,000 shares of common stock following a 10-for-1 reverse stock split.

Harvard Bioscience Director William Snider increased his direct ownership of common stock following a 10-for-1 reverse stock split.

Harvard Bioscience CEO John D. Duke purchased 5,000 shares of common stock and disclosed details of his restricted stock unit awards, including performance-based vesting conditions.

Harvard Bioscience Director William Snider received an award of 110,000 restricted stock units that will vest in December 2026.

Stephen J. DeNelsky, a director at Harvard Bioscience, received an award of 110,000 restricted stock units vesting in 2026.

James W. Green, a Director at Harvard Bioscience Inc., forfeited over 392,000 shares of common stock and RSUs following his resignation from all services with the company.

Harvard Bioscience CEO John D. Duke received 1 million restricted stock units, split between time-based and performance-based vesting conditions.

Harvard Bioscience Director Seth Benjamin Benson was awarded 110,000 restricted stock units, vesting by July 2026.

Harvard Bioscience Inc. Director Katherine A. Eade was granted 110,000 restricted stock units, aligning her interests with long-term shareholder value.

Harvard Bioscience Inc. Director Robert E. Gagnon was granted 110,000 restricted stock units, aligning his interests with shareholders.

Mark T. Frost, Interim CFO of Harvard Bioscience, Inc., acquired 100,000 restricted stock units on May 12, 2025, according to a Form 4 filing.

Jennifer Cote, CFO of Harvard Bioscience, disposed of 5,687 shares of common stock on March 19, 2025, to satisfy tax withholding obligations related to vested restricted stock units.

James W. Green, CEO of Harvard Bioscience, disposed of shares to cover tax obligations related to vested restricted stock units.

James W. Green, CEO of Harvard Bioscience, forfeited 145,365 performance-based restricted stock units on December 31, 2024, following the final determination of applicable performance conditions.

Harvard Bioscience CEO James W. Green disposed of shares to cover tax obligations following the vesting of restricted stock units.

Harvard Bioscience's Chief Financial Officer, Jennifer Cote, sold shares to cover tax obligations related to vested restricted stock units.

James W. Green, CEO of Harvard Bioscience, recently purchased 10,000 shares of the company's common stock at a price of $2.91 per share.

Harvard Bioscience's CEO, James W. Green, recently purchased 20,000 shares of the company's common stock at an average price of $3.07 per share.

Director Bertrand Loy reports acquiring 56,575 restricted stock units in Harvard Bioscience, Inc.

Director Thomas W. Loewald of Harvard Bioscience, Inc. acquired 45,872 shares of common stock through a restricted stock unit award on May 21, 2024.

Director Katherine Eade reports acquisition of 45,872 restricted stock units in Harvard Bioscience, Inc.

Director Alan I. Edrick acquired 45,872 restricted stock units in Harvard Bioscience Inc. on May 21, 2024.